Relative Bioavailability Study of CC-292

NCT ID: NCT02433457

Last Updated: 2020-08-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-26
• Study Completion Date: 2014-09-26

Brief Summary

To evaluate the PK profile of the newly developed CC-292 SDD formulation compared to CC-292 P22 tablet.

Detailed Description

This is a single center, open-label, randomized, seven-treatment, seven-period, crossover design. The study will consist of a screening phase, a treatment phase, and a follow-up phone call. Approximately 24 healthy adult subjects (male or female) will be enrolled.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition

Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

CC-292 SDD 300mg - Fed Condition

Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

375mg P22 - Fasted condition

Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

375mg P22 Fed Condition

Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

CC-292 SDD 100 mg Fasted Condition

Single oral dose of 100 mg CC-292 SDD under fasted conditions

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

SDD plus OMP (Oral Omeprazole)

Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

Oral Omeprazole (OMP)

Intervention Type: DRUG

P22 plus OMP

Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP

Group Type: EXPERIMENTAL

CC-292

Intervention Type: DRUG

Oral Omeprazole (OMP)

Intervention Type: DRUG

Interventions

CC-292

Intervention Type: DRUG

Oral Omeprazole (OMP)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Must understand and voluntarily sign a written Informed Consent Form (ICF) prior to any study-related assessments/procedures being conducted.

2. Must be able to communicate with the Investigator, understand, and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.

3. Must be a male or female subject from any race between 18 to 65 years of age (inclusive) at the time of signing the ICF, and in good health as determined by Physical Examinations (PE).

4. Must comply with the following acceptable forms of contraception:

1. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception with male condoms NOT made out of natural animal membrane (e.g., latex or polyurethane condoms are acceptable) while on study drug, and for at least 90 days after the last dose of study drug.

2. Females of childbearing potential (FCBP) 1 must have a negative pregnancy test at Screening and at Baseline (i.e., on Day -1). FCBP who engage in activity in which conception is possible must agree to use one of the following forms of contraception during their entire participation in the study and for at least 30 days after administration of the last dose of study drug:

• Option 1: Any one of the following: non-oral hormonal contraception (e.g., injection, implant, transdermal patch, vaginal ring); intrauterine device; tubal ligation; or a partner with a vasectomy; OR
• Option 2: Oral contraceptive pills PLUS one additional barrier method of the following: (a) male or female condom NOT made out of natural animal membrane (e.g., latex or polyurethane is acceptable); (b) diaphragm with spermicide; (c) cervical cap with spermicide; or (d) contraceptive sponge with spermicide; OR
• Option 3: TWO of the following barrier methods: (a) male or female condom NOT made out of natural animal membrane (e.g., latex or polyurethane is acceptable); (b) diaphragm with spermicide; (c) cervical cap with spermicide; or (d) a contraceptive sponge with spermicide.

Note: All other females must have been surgically sterilized for at least 6 months before Screening (proper documentation required), or be postmenopausal (defined as 24 months without menses before Screening, and an estradiol level of < 30 pg/mL and a plasma Follicle Stimulating Hormone (FSH) level > 40 IU/L at Screening).

5. Must have a Body Mass Index (BMI) between 18 and 33 kg/m2 (inclusive).

6. No clinically significant laboratory test results, as determined by the Investigator.

7. Must be afebrile, with supine systolic BP of 90 to 140 mmHg, a supine diastolic Blood Pressure (BP) of 60 to 90 mmHg, and pulse rate of 40 to 110 bpm.

8. Must have a normal or clinically acceptable 12-lead Electrocardiogram (ECG) at Screening. Male subjects must have a QTcF value ≤ 430 msec. Female subjects must have a QTcF value ≤ 450 msec.

Exclusion Criteria

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, or confounds the ability to interpret data from the study.

3. Use of any prescribed systemic or topical medication (including but not limited to antibiotics, analgesics, anesthetics, etc.) prior to 30 days of the first dose administration, unless Sponsor agreement is obtained.

4. Use of any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 7 days of the first dose administration, unless Sponsor agreement is obtained.

5. Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism and excretion (e.g., bariatric procedure), or plans to have elective or medical procedures during the conduct of the trial. Subjects post cholecystectomy and post appendectomy may be included.

6. Exposure to an investigational drug within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).

7. Donated blood or plasma prior to 4 weeks before the first dose administration to a blood bank or blood donation center.

8. History of multiple drug allergies (i.e., two or more);

9. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) prior to 2 years before first dose administration, or a positive drug screen reflecting consumption of illicit drugs.

10. History of alcohol abuse (as defined by the current version of the DSM) prior to 2 years before dosing, or a positive alcohol screen.

11. Known to have hepatitis, or known to be a carrier of the Hepatitis B Surface Antigen (HBsAg), or Hepatitis C Virus Antibody (HCVAb), or have a positive result to the test for HBsAg, HCVAb, or Human Immunodeficiency Virus (HIV) antibodies at Screening.

12. History of smoking or the use of nicotine containing products prior to 3 months of Screening by self reporting.

13. Female subjects lactating or breastfeeding a child.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel Weiss, MD

Role: STUDY_DIRECTOR

Celgene Corporation

Locations

Covance Clinical Research unit

Evansville, Indiana, United States

Countries

United States

References

Cheng Y, Liu L, Xue Y, Zhou S, Li Y. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor. Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):579-592. doi: 10.1007/s13318-022-00776-7. Epub 2022 Jun 3.

Reference Type: DERIVED

PMID: 35657581 (View on PubMed)

Other Identifiers

CC-292-CP-002

Identifier Type: -

Identifier Source: org_study_id